 | |
| Clinical data | |
|---|---|
| Trade names | Teveten |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a601237 |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 15% (Eprosartan mesylate) |
| Metabolism | not metabolized |
| Eliminationhalf-life | 5 to 9 hours |
| Excretion | Kidney 10%,bile duct 90% |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C23H24N2O4S |
| Molar mass | 424.52 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Eprosartan, sold under the brand nameTeveten among others, is anangiotensin II receptor antagonist used for the treatment ofhigh blood pressure.[1]
Eprosartan is sometimes paired withhydrochlorothiazide.[2]
As with other angiotensin II receptor antagonists, eprosartan is generally better tolerated thanenalapril (anACE inhibitor), especially among the elderly.[3]
The compound came into theAbbott Laboratories cardiovascular pipeline with its acquisition ofKos Pharmaceuticals in 2006, which had licensed it, along with "a range of hypertensive treatments", from theBiovail Corporation.[4]
